---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-021732"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:40:43.448538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix cross-licenses iSPERSE with MannKind; transfers Bedford R&D facility to extend cash runway

## Summary
- Pulmatrix grants MannKind exclusive iSPERSE licenses for clofazimine, NTM lung disease, insulin; non-exclusive for endocrine, ILD.
- MannKind grants Pulmatrix exclusive Cricket device license for PUR3100 (DHE/migraine); non-exclusive for neurological disease.
- MannKind assumes Pulmatrix's Bedford R&D facility lease and equipment; expected close July 2024.
- CEO: transaction validates iSPERSE technology and extends cash runway into 2026.
- MannKind to provide development services under MSA and may hire some Pulmatrix R&D staff.

## SEC filing metadata
- accession: 0001493152-24-021732
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315224021732/0001493152-24-021732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315224021732/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-021732
- JSON: https://secwatch.observer/filing/0001493152-24-021732.json
- Plain text: https://secwatch.observer/filing/0001493152-24-021732.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.